The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.o

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

Publications

DUSTAN HP, TAYLOR RD, CORCORAN AC

Rheumatic and febrile syndrome during prolonged hydralazine treatment.

Journal of the American Medical Association 1954 Jan 02;154;23-9 — 1954 Jan 02 — 23-9

Peacock A, Weatherall D

Hydralazine-induced necrotising vasculitis.

British medical journal (Clinical research ed.) 1981 Apr 04;282;1121-2 — 1981 Apr 04 — 1121-2

Martinez-Vea A, Ferrer I, Carcía C, Mayayo E, Oliver JA, Richart C

Systemic vasculitis resembling periarteritis nodosa in the lupus-like syndrome induced by hydralazine.

American journal of nephrology 1987;7;71-3 — 1987 — 71-3